文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

IW-3718可减轻难治性胃食管反流病患者烧心严重程度:一项随机试验

IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial.
PubMed 文献 · Gastroenterology · 2020-02-22

该多中心双盲安慰剂对照试验纳入280例确诊GERD且持续使用标签剂量PPI的患者,按食管炎状态分层后随机接受安慰剂或IW-3718 500/1000/1500 mg每日两次治疗8周。结果显示,1500 mg组第8周每周烧心严重程度评分较基线下降58.0%,安慰剂组下降46.0%,组间差异11.9%(P=.04),反流频率评分亦下降;最常见不良事件为便秘,未出现药物相关严重不良事件。

要点

  • 在标签剂量PPI基础上加用IW-3718 1500 mg每日两次可显著改善难治性GERD烧心症状。
  • 烧心严重程度评分改善呈剂量反应关系(剂量反应P=.02)。
  • IW-3718总体耐受性良好,最常见不良事件为便秘。

核心结论

  • 在难治性GERD患者中,在标签剂量PPI基础上加用IW-3718 1500 mg每日两次,与加用安慰剂相比可显著减轻烧心症状,反流症状亦减少,且耐受性良好。

研究设计与样本

  • 多中心、双盲、安慰剂对照试验,2016年3月至2017年4月纳入280例确诊GERD患者。
  • 患者按食管炎状态分层,按1:1:1:1随机分为安慰剂组或IW-3718 500、1000、1500 mg组,每日两次,同时继续使用标签剂量PPI。
  • 主要终点为第8周每周烧心严重程度评分较基线的百分比变化。

主要发现

  • 第8周每周烧心严重程度评分较基线平均下降:安慰剂组46.0%,500 mg组49.0%,1000 mg组55.1%,1500 mg组58.0%(剂量反应P=.02)。
  • 1500 mg组与安慰剂组之间的治疗差异为11.9%(P=.04,协方差分析)。
  • 第8周每周反流频率评分较基线平均下降:1500 mg组与安慰剂组相比为17.5%(95%CI为31.4%至3.6%)。
  • 最常见不良事件为便秘,IW-3718组发生率为8.1%,安慰剂组为7.1%;无药物相关严重不良事件。

临床怎么用

  • 对于接受标签剂量PPI后仍有烧心症状的难治性GERD患者,可考虑在PPI基础上加用胆汁酸螯合剂IW-3718 1500 mg每日两次以进一步减轻烧心与反流症状。
  • 用药期间关注便秘等不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Refractory gastroesophageal reflux disease (GERD) reduces quality of life and creates significant financial burden on the health care system. Approximately 30% of patients with GERD who receive label-dose proton pump inhibitors (PPIs) still have symptoms. We performed a trial to evaluate the efficacy and safety of IW-3718, a bile acid sequestrant, as an adjunct to PPI therapy. METHODS: We performed a multicenter, double-blind, placebo-controlled trial, from March 2016 through April 2017, of 280 patients with confirmed GERD. The patients, stratified by esophagitis status, were randomly assigned (1:1:1:1) to groups given placebo or IW-3718 (500, 1000, or 1500 mg) twice daily, with ongoing label-dose PPI. The primary endpoint was percent change from baseline to week 8 in weekly heartburn severity score. We also analyzed percent change from baseline to week 8 in weekly regurgitation frequency score. RESULTS: Mean changes from baseline to week 8 in weekly heartburn severity scores were reductions of 46.0% in the placebo group, 49.0% in the 500 mg group, 55.1% in the 1000 mg group, and 58.0% in the 1500 mg IW-3718 group (dose-response P = .02). The treatment difference was 11.9% between the 1500 mg IW-3718 and placebo groups (P = .04, analysis of covariance). The mean change in weekly regurgitation frequency score from baseline to week 8 in the 1500 mg IW-3718 vs placebo groups was a reduction of 17.5% (95% confidence interval, reductions of 31.4% to 3.6%). The most common adverse event was constipation (in 8.1% of patients receiving IW-3718 and 7.1% of patients receiving placebo). There were no drug-related serious adverse events. CONCLUSIONS: In a randomized trial of patients with refractory GERD, adding 1500 mg IW-3718 to label-dose PPIs significantly reduced heartburn symptoms compared with adding placebo. Regurgitation symptoms also decreased. IW-3718 was well tolerated. (ClinicalTrials.gov, Number: NCT02637557).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Vaezi MF, Fass R, Vakil N, et al. IW-3718 Reduces Heartburn Severity in Patients With Refractory Gastroesophageal Reflux Disease in a Randomized Trial. Gastroenterology. 2020. PMID: 32092310. doi:10.1053/j.gastro.2020.02.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。